Herpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort Study

English version České info

Background:
Herpes zoster is common and has serious consequences, notably post-herpetic neuralgia (PHN). Vaccine efficacy against incident zoster and PHN has been demonstrated in clinical trials, but effectiveness has not been studied in unselected general populations unrestricted by region, full health insurance coverage, or immune status. Our objective was to assess zoster vaccine effectiveness (VE) against incident zoster and PHN in a general population-based setting.

Methods and Findings:
A cohort study of 766,330 fully eligible individuals aged ≥65 years was undertaken in a 5% random sample of Medicare who received and did not receive zoster vaccination between 1st January 2007 and 31st December 2009.

Incidence rates and hazard ratios for zoster and PHN were determined in vaccinated and unvaccinated individuals. Analyses were adjusted for age, gender, race, low income, immunosuppression, and important comorbidities associated with zoster, and then stratified by immunosuppression status. Adjusted hazard ratios were estimated using time-updated Cox proportional hazards models.

Vaccine uptake was low (3.9%) particularly among black people (0.3%) and those with evidence of low income (0.6%). 13,112 US Medicare beneficiaries developed incident zoster; the overall zoster incidence rate was 10.0 (9.8–10.2) per 1,000 person-years in the unvaccinated group and 5.4 (95% CI 4.6–6.4) per 1,000 person-years in vaccinees, giving an adjusted VE against incident zoster of 0.48 (95% CI 0.39–0.56). In immunosuppressed individuals, VE against zoster was 0.37 (95% CI 0.06–0.58). VE against PHN was 0.59 (95% CI 0.21–0.79).

Conclusions:
Vaccine uptake was low with variation in specific patient groups. In a general population cohort of older individuals, zoster vaccination was associated with reduction in incident zoster, including among those with immunosuppression. Importantly, this study demonstrates that zoster vaccination is associated with a reduction in PHN.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Herpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort Study. PLoS Med 10(4): e32767. doi:10.1371/journal.pmed.1001420
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001420

Souhrn

Zdroje

1. YawnBP, SaddierP, WollanPC, St SauverJL, KurlandMJ, et al. (2007) A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 82: 1341–1349.

2. JohnsonRW, BouhassiraD, KassianosG, LeplègeA, SchmaderKE, et al. (2010) The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 8: 37.

3. OxmanM, LevinM, JohnsonG, SchmaderK, StrausS, et al. (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352: 2271–2284.

4. SchmaderKE, LevinMJ, GnannJW, McNeilSA, VesikariT, et al. (2012) Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis 54: 922–928.

5. TsengHF, SmithN, HarpazR, BialekSR, SyLS, et al. (2011) Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 305: 160–166.

6. ZhangJ, XieF, DelzellE, ChenL, WinthropKL, et al. (2012) Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 308: 43–49.

7. HarpazR, Ortega-SanchezI, SewardJ (2008) Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 57: 1–30; quiz CE32–34.

8. GeboK, KalyaniR, MooreR, PolydefkisM (2005) The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 40: 169–174.

9. StrangfeldA, ListingJ, HerzerP, LiebhaberA, RockwitzK, et al. (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301: 737–744.

10. GourishankarS, McDermidJ, JhangriG, PreiksaitisJ (2004) Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 4: 108–115.

11. SonM, ShapiroED, LaRussaP, NeuN, MichalikDE, et al. (2010) Effectiveness of varicella vaccine in children infected with HIV. J Infect Dis 201: 1806–1810.

12. GershonAA, LevinMJ, WeinbergA, SongLY, LaRussaPS, et al. (2009) A phase I–II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J 28: 653–655.

13. Center for Medicare and Medicaid Services (2009) Center for Medicare and Medicaid Services 2009 data compendium. Baltimore (Maryland): Center for Medicare and Medicaid Services.

14. KlompasM, KulldorffM, VilkY, BialekSR, HarpazR (2011) Herpes zoster and postherpetic neuralgia surveillance using structured electronic data. Mayo Clin Proc 86: 1146–1153.

15. ThomasS, HallA (2004) What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 4: 26–33.

16. YawnBP, WollanP, St SauverJ (2011) Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they? Am J Epidemiol 174: 1054–1061.

17. DonahueJ, ChooP, MansonJ, PlattR (1995) The incidence of herpes zoster. Arch Intern Med 155: 1605–1609.